Assetmark Inc. Has $44,000 Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Assetmark Inc. grew its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 77.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,225 shares of the medical device company’s stock after purchasing an additional 535 shares during the quarter. Assetmark Inc.’s holdings in Tandem Diabetes Care were worth $44,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of TNDM. Crossmark Global Holdings Inc. bought a new stake in Tandem Diabetes Care during the third quarter valued at $200,000. State of New Jersey Common Pension Fund D grew its position in shares of Tandem Diabetes Care by 24.6% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 44,776 shares of the medical device company’s stock worth $1,899,000 after buying an additional 8,837 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at $263,000. Victory Capital Management Inc. lifted its position in shares of Tandem Diabetes Care by 45.6% during the 3rd quarter. Victory Capital Management Inc. now owns 587,247 shares of the medical device company’s stock valued at $24,905,000 after acquiring an additional 183,877 shares during the period. Finally, Oppenheimer Asset Management Inc. boosted its stake in Tandem Diabetes Care by 20.1% during the third quarter. Oppenheimer Asset Management Inc. now owns 59,092 shares of the medical device company’s stock worth $2,506,000 after acquiring an additional 9,899 shares in the last quarter.

Tandem Diabetes Care Price Performance

NASDAQ TNDM opened at $19.17 on Friday. Tandem Diabetes Care, Inc. has a 52 week low of $17.64 and a 52 week high of $53.69. The company has a market cap of $1.27 billion, a PE ratio of -9.93 and a beta of 1.45. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The firm’s 50-day simple moving average is $31.38 and its two-hundred day simple moving average is $34.62.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on TNDM shares. Barclays dropped their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Citigroup lowered shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $24.00 in a report on Tuesday, March 4th. The Goldman Sachs Group dropped their price target on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Finally, Robert W. Baird decreased their price objective on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a report on Thursday, February 27th. Eight investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.38.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos bought 10,538 shares of Tandem Diabetes Care stock in a transaction on Friday, March 7th. The stock was acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares of the company’s stock, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.20% of the company’s stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.